Here are the 10-K annual reports from Oncolytics Biotech, Inc. (ONCY) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ONCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONCY filings page.
Oncolytics Biotech Inc. files its annual report as a clinical-stage biotech focused on developing pelareorep, an intravenously delivered oncolytic virus immunotherapy for multiple cancers, especially gastrointestinal and breast tumors. The company has no approved products and does not expect significant revenue until pelareorep is commercialized.
Management discloses substantial doubt about its ability to continue as a going concern over the next 12 months, citing recurring losses and limited cash, and states that continued operations depend on raising additional capital. The filing details extensive clinical data, patent protection into at least 2031 with new applications potentially extending into the 2040s, and outlines intense competition and significant regulatory, financing, and execution risks, including an ongoing corporate domestication process from Canada to Nevada.